BioLineRx Ltd. (NASDAQ: BLRX) stock is up nearly 28 percent to hit $4.3 in pre-market trading, considering the Bio-tech company’s lack of reports or news releases. And what do you want to discover? And why is today’s BLRX stock trending higher? Here’s the latest update for investors to learn about BioLineRx Ltd (NASDAQ: BLRX).
An oncology-focused, late clinical-stage biotech firm officially posted and offered a corporate overview of its financial performance for the quarter ended September 30, 2020.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The company posted positive findings from a pre-planned interim review of the GENESIS Phase 3 stem cell mobilization motixafortide trial in multiple myeloma patients have been published. The Data Management Committee considered statistically relevant evidence supporting primary endpoint care of motixafortide and eventually released a recommendation to halt patient registration promptly. The research registration of 122 patients was performed according to the DMC guideline (instead of 177 as originally planned). SCM is the most successful registration route for the Company;
BLRX also reported initiation of the investigator-initiated Phase 2 analysis of motixafortide in conjunction with LIBTAYO and first-line PDAC chemotherapy. Columbia University is conducting the research;
Moreover, it reported initiation of a Phase 1b investigator-initiated analysis to test motixafortide in patients hospitalized with acute respiratory distress syndrome (ARDS) secondary to COVID-19 and other respiratory viral infections, performed by Wolfson Medical Center in Holon, Israel;